Hospital
Winchester Hospital
Winchester Hospital was paid $30.25M by Medicaid between Jan 2018 and Dec 2024, across 293 billing codes. Its largest line is 99285, emergency room visit (most serious) — 13% of everything it billed.
33Billing provider infoWINCHESTER HOSPITAL
WINCHESTER, MA 01890
WINCHESTER, MA 01890
33aNPI1790740777assigned 04/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.25M
24GClaims1,002,295
24DCodes billed293
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#33 of 66
Median peer was paid$29.11M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 115,343 | $3.48M | |
| 2019 | 129,664 | $3.60M | |
| 2020 | 116,037 | $2.95M | |
| 2021 | 156,287 | $4.39M | |
| 2022 | 170,337 | $5.42M | |
| 2023 | 176,857 | $5.74M | |
| 2024incomplete | 137,770 | $4.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 25,324 | 22,633 | $3.83M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 9,925 | 8,614 | $3.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 20,914 | 19,655 | $3.29M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.6% | 14,127 | 13,172 | $2.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 12,679 | 11,798 | $1.77M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.0% | 11,265 | 10,565 | $1.22M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 14,980 | 4,462 | $845K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 4,643 | 4,290 | $732K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 4,213 | 4,059 | $674K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 5,123 | 4,783 | $616K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 5,715 | 5,185 | $579K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 7,377 | 6,843 | $520K |
281 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 1.7% | 3,643 | $506K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 3,720 | $421K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 15,305 | $389K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.3% | 4,593 | $379K |
| G0378 | Hospital observation service, per hour | 1.1% | 7,210 | $332K |
| S9485 | Crisis intervention mental health services, per diem | 1.1% | 517 | $321K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 3,404 | $313K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,833 | $278K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,392 | $263K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,764 | $256K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,161 | $253K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,957 | $243K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,012 | $224K |
| 76830 | Ultrasound, transvaginal | <1% | 2,524 | $220K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,381 | $202K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 180 | $177K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,930 | $168K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,287 | $167K |
| 80053 | Comprehensive metabolic panel | <1% | 33,996 | $156K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,368 | $154K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,055 | $150K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 122 | $141K |
| 84702 | <1% | 12,293 | $134K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,262 | $131K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,716 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,507 | $113K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,629 | $104K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,749 | $101K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,069 | $95K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 599 | $94K |
| 84484 | <1% | 11,246 | $89K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,004 | $87K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 753 | $86K |
| 80050 | General health panel | <1% | 5,357 | $84K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,909 | $84K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,343 | $81K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,757 | $81K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,151 | $81K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,726 | $80K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,811 | $74K |
| 87081 | <1% | 13,132 | $74K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,840 | $74K |
| 85027 | <1% | 19,154 | $72K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 43 | $69K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 856 | $68K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,698 | $67K |
| 80061 | Lipid panel | <1% | 21,980 | $67K |
| 82607 | <1% | 8,270 | $67K | |
| 76642 | <1% | 561 | $63K | |
| 82728 | <1% | 7,860 | $61K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,726 | $60K |
| J3490 | Unclassified drugs | <1% | 3,157 | $54K |
| ATP08 | <1% | 10,575 | $54K | |
| 86803 | <1% | 4,466 | $53K | |
| 73630 | <1% | 2,145 | $51K | |
| 87480 | <1% | 2,794 | $49K | |
| 86780 | <1% | 3,632 | $46K | |
| 87510 | <1% | 2,793 | $46K | |
| 87660 | <1% | 2,793 | $45K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 887 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,558 | $42K |
| 93971 | <1% | 680 | $41K | |
| 81003 | <1% | 29,510 | $40K | |
| 84466 | <1% | 5,898 | $40K | |
| 73562 | <1% | 1,659 | $37K | |
| 83690 | <1% | 8,226 | $36K | |
| 76770 | <1% | 259 | $36K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,021 | $36K |
| 86850 | <1% | 4,783 | $36K | |
| 83735 | <1% | 9,942 | $34K | |
| 73610 | <1% | 1,049 | $34K | |
| 97803 | <1% | 424 | $34K | |
| 87186 | <1% | 6,057 | $31K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 221 | $29K |
| 87077 | <1% | 5,698 | $28K | |
| 83655 | <1% | 2,352 | $27K | |
| 87340 | <1% | 2,910 | $26K | |
| 87070 | <1% | 4,283 | $26K | |
| 82746 | <1% | 3,280 | $25K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 257 | $25K |
| 86140 | <1% | 6,721 | $25K | |
| 83540 | <1% | 6,891 | $25K | |
| ATP15 | <1% | 3,544 | $25K | |
| 84439 | <1% | 4,229 | $24K | |
| 84153 | <1% | 1,758 | $23K | |
| 87147 | <1% | 3,044 | $22K | |
| 81514 | <1% | 228 | $21K | |
| 87088 | <1% | 4,344 | $21K | |
| 81025 | <1% | 3,560 | $20K | |
| 85610 | <1% | 13,340 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 176 | $18K |
| 85379 | <1% | 2,751 | $18K | |
| 76801 | <1% | 253 | $16K | |
| 74019 | <1% | 426 | $16K | |
| 74018 | <1% | 337 | $16K | |
| 73130 | <1% | 719 | $16K | |
| 86762 | <1% | 1,072 | $15K | |
| 86618 | <1% | 789 | $15K | |
| ATP14 | <1% | 4,884 | $14K | |
| ATP17 | <1% | 5,960 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,862 | $14K |
| 82248 | <1% | 11,758 | $13K | |
| 82784 | <1% | 1,431 | $13K | |
| 83880 | <1% | 1,314 | $13K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 229 | $12K |
| 73030 | <1% | 499 | $12K | |
| 86900 | <1% | 4,832 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,186 | $11K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 65 | $11K |
| 80076 | <1% | 4,087 | $11K | |
| 84403 | <1% | 516 | $11K | |
| 86480 | <1% | 204 | $11K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 113 | $11K |
| 59025 | Fetal non-stress test | <1% | 36 | $11K |
| 86901 | <1% | 4,828 | $10K | |
| 80179 | <1% | 1,200 | $10K | |
| 82043 | <1% | 4,316 | $10K | |
| 87040 | <1% | 1,106 | $10K | |
| 97035 | <1% | 240 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 275 | $9K |
| 77066 | Tomosynthesis, mammo | <1% | 59 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 46 | $9K |
| 82565 | <1% | 3,535 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 57 | $9K |
| 82150 | <1% | 1,774 | $8K | |
| 83516 | <1% | 367 | $8K | |
| 73110 | <1% | 371 | $8K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 14 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,907 | $7K |
| 99220 | <1% | 25 | $7K | |
| 82570 | <1% | 2,814 | $7K | |
| 87205 | <1% | 2,567 | $7K | |
| 82077 | <1% | 1,208 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,457 | $7K |
| 88342 | <1% | 87 | $7K | |
| 76536 | <1% | 68 | $7K | |
| ATP03 | <1% | 2,332 | $7K | |
| 87634 | <1% | 115 | $7K | |
| 80143 | <1% | 976 | $6K | |
| 82947 | <1% | 1,562 | $6K | |
| 85652 | <1% | 3,501 | $6K | |
| 73140 | <1% | 226 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,310 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,518 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 44,617 | $6K |
| 87420 | <1% | 467 | $5K | |
| 80306 | <1% | 1,487 | $5K | |
| 83970 | <1% | 586 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,578 | $5K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $5K |
| 86038 | <1% | 483 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,690 | $5K |
| 84450 | <1% | 2,000 | $5K | |
| 86706 | <1% | 432 | $5K | |
| 86364 | <1% | 398 | $5K | |
| 97802 | <1% | 44 | $5K | |
| 87150 | <1% | 254 | $4K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 26 | $4K |
| 86665 | <1% | 125 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 216 | $4K |
| 99218 | <1% | 145 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,286 | $4K |
| 90714 | <1% | 213 | $4K | |
| 84550 | <1% | 3,196 | $3K | |
| 84460 | <1% | 2,741 | $3K | |
| 84100 | <1% | 4,030 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,632 | $3K |
| 83001 | <1% | 187 | $3K | |
| 97161 | <1% | 39 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,958 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,629 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,463 | $3K |
| 12001 | <1% | 12 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 61 | $3K |
| 97162 | <1% | 79 | $2K | |
| 71271 | <1% | 39 | $2K | |
| 72110 | <1% | 66 | $2K | |
| 84520 | <1% | 2,560 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $2K |
| 86704 | <1% | 196 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 12 | $2K |
| 83550 | <1% | 369 | $2K | |
| 84146 | <1% | 111 | $2K | |
| 82962 | <1% | 3,873 | $2K | |
| 70498 | <1% | 15 | $2K | |
| ATP11 | <1% | 670 | $2K | |
| 82550 | <1% | 1,351 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,637 | $2K |
| 83605 | <1% | 232 | $2K | |
| ATP16 | <1% | 329 | $2K | |
| 86664 | <1% | 112 | $2K | |
| ATP09 | <1% | 512 | $1K | |
| 86787 | <1% | 116 | $1K | |
| 85730 | <1% | 609 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 770 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,842 | $1K |
| 84703 | <1% | 250 | $1K | |
| 87427 | <1% | 92 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 25 | $1K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 123 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 787 | $1K |
| 82670 | <1% | 47 | $1K | |
| 84270 | <1% | 56 | $1K | |
| 87046 | <1% | 157 | $1K | |
| 73080 | <1% | 65 | $1K | |
| S5161 | Emergency response system; service fee, per month (excludes installation and testing) | <1% | 45 | $1K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 30 | $1K |
| 86003 | <1% | 13 | $920.00 | |
| 85018 | <1% | 395 | $903.12 | |
| 84156 | <1% | 396 | $876.16 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 128 | $858.86 |
| 80305 | <1% | 119 | $763.33 | |
| 85014 | <1% | 349 | $755.78 | |
| 86308 | <1% | 172 | $748.46 | |
| 93017 | <1% | 17 | $739.49 | |
| 83002 | <1% | 45 | $735.66 | |
| 86258 | <1% | 50 | $732.78 | |
| 83721 | <1% | 95 | $708.88 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 17 | $701.76 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 278 | $697.69 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $650.04 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 223 | $606.47 |
| 87045 | <1% | 104 | $559.98 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $537.65 |
| ATP10 | <1% | 181 | $525.07 | |
| 81001 | <1% | 315 | $523.93 | |
| 77080 | <1% | 28 | $523.20 | |
| ATP18 | <1% | 231 | $506.27 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 570 | $465.92 |
| 80164 | <1% | 158 | $419.19 | |
| 73502 | <1% | 82 | $417.72 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 971 | $352.45 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 761 | $342.27 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 442 | $277.79 |
| 71250 | <1% | 13 | $246.55 | |
| 84478 | <1% | 306 | $231.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,174 | $209.71 |
| ATP07 | <1% | 61 | $202.32 | |
| 85045 | <1% | 58 | $193.60 | |
| 96376 | <1% | 1,042 | $177.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 56 | $155.11 |
| 86430 | <1% | 25 | $145.56 | |
| 88312 | <1% | 77 | $135.88 | |
| 87449 | <1% | 13 | $131.28 | |
| 87324 | <1% | 12 | $131.28 | |
| 73090 | <1% | 12 | $110.32 | |
| 87015 | <1% | 18 | $102.81 | |
| 82948 | <1% | 14 | $93.24 | |
| ATP02 | <1% | 76 | $91.29 | |
| ATP04 | <1% | 19 | $57.92 | |
| 82330 | <1% | 33 | $57.44 | |
| 85380 | <1% | 15 | $52.50 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 135 | $47.30 |
| 84480 | <1% | 14 | $43.83 | |
| 70496 | <1% | 27 | $40.11 | |
| 82247 | <1% | 15 | $31.99 | |
| 83615 | <1% | 28 | $22.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,202 | $20.54 |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $14.54 |
| 84132 | <1% | 16 | $4.73 | |
| 82310 | <1% | 47 | $4.71 | |
| 88304 | 0% | 28 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 18 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 504 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 558 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 128 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| 80051 | 0% | 68 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 17 | $0.00 |
| 71101 | 0% | 15 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,421 | $0.00 |
| 99152 | 0% | 280 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 42 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 30 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 52 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 26 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 89 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 41 | $0.00 |
| 71010 | 0% | 14 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 23 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOODS, MATTHEW (CFO)
Parent organizationWINCHESTER HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Woods Dental Services PLLC | Conway, AR | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.